Introduction: Minimal manifestation (MM) or better was recommended as the treatment goal for myasthenia gravis (MG). The sustainability of this status has not been described quantitatively in patients who had attained or are close to it.
Methods: Patients who were with no or slight impact on daily living were recruited and followed at baseline and 3, 6, and 12 months.